Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen

Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen

Physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) models can serve as a powerful framework for predicting the influence as well as the interaction of formulation, genetic polymorphism and co-medication on the pharmacokinetics and pharmacodynamics of drug substances. In this study, flur...

Full description

Bibliographic Details
Main Authors: Ioannis Loisios-Konstantinidis, Rodrigo Cristofoletti, Masoud Jamei, David Turner, Jennifer Dressman
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Pharmaceutics
Subjects:
physiologically based pharmacokinetic (PBPK) modeling
pharmacokinetics/pharmacodynamics (PK/PD)
<i>in vitro in vivo</i> extrapolation (IVIVE)
mechanistic oral absorption modeling
drug–drug interaction (DDI)
pharmacogenetics
Online Access:https://www.mdpi.com/1999-4923/12/11/1049

Internet

https://www.mdpi.com/1999-4923/12/11/1049

Similar Items